News & Comment

This week, deals are announced by Eisai, Roivant and Sanofi amongst others.

A lean, entrepreneurial approach is enabling specialty pharma company EUSA Pharma to outcompete larger rivals.

Carrick Therapeutics is collaborating with a network of researchers and partners to build an innovative portfolio of first-in-class treatments that target multiple mechanisms of the most aggressive forms of cancer.

ImmuneOncia Therapeutics is developing antibodies that target novel immune checkpoints, which could enhance drug efficacy when used in combination with agents that block PD-1 or PD-L1.

The week’s announcements began with news from AstraZeneca.

Arquer Diagnostics is developing a series of innovative, non-invasive tests for cancer and recently launched ADXBLADDER, a reliable urine test for bladder cancer.

Oncology is currently the leading area for dealmaking, driven by immuno-oncology, which accounted for 32 of the 35 multibillion-dollar oncology licensing deals of the last five years. In this feature, authors at Clarivate Analytics explore the recent trends in oncology deals.

Last week saw another string of high-value deals from the likes of AbbVie, Gilead and Merck & Co., welcome to our weekly round up.

Whilst many of the world’s infectious diseases are managed well due to advances in scientific research, drug-resistant bacterial infections and emerging pathogenic viruses such as Zika still continue to pose major and pressing threats to public health.

Bristol-Myers Squibb (BMS) broke records for the highest licensing fee with its potential $3.8 billion deal with Nektar Therapeutics last Wednesday.

The past week has seen a couple of 1-billion-dollar deals. First, Janssen signed a potential $1 billion deal with Theravance.

As we take our first steps into February, dealmaking activity has quietened down from the boom in recent weeks, but there was still another major M&A announced.

The past week has seen another major M&A deal for the year and it’s not even the end of January.

Two major M&A deals announced today could boost hopes for a spike in dealmaking activity.

Dealmaking has already started in earnest in 2018, with at least 20 deals signed in only the first two weeks. Many of these coincided with the annual JP Morgan conference that has just come to a close, and many of them involve big pharma.

Competition for promising investigational drugs remains fierce, with many assets snapped up before they have even started clinical trials. With the annual JP Morgan conference— typically an event where major deals are announced — now in progress, here we highlight some of the most valuable assets that are currently unpartnered, using data provided by EvaluatePharma.